Retina Surgeon

Hello world!

January 1st 2014

“Congratulations to our dedicated and dynamic research team on successfully securing a research grant from the Seeing is Believing Innovation Fund for 2014!” We reached the final 8 of 290 eligible proposals from 257 organisations across 53 countries.  Following an eight stage review process, our application was one of eight applications recommended for immediate funding. This research project has fantastic educational and training implications for healthcare professionals in the developing world who are involved in diabetic eye screening programs in their home countries. I am looking forward to working with our team this year.”

“The focus of the SiB Innovation Fund is to stimulate innovation in the global campaign to eliminate avoidable blindness, VISION 2020, by supporting various organisations and bodies to test and deliver creative approaches to eye care.”

February 26th 2014

“The Royal College of Ophthalmologists welcomes the Final Appraisal Determination from the National Institute for Health and Care Excellence (NICE) recommending Eylea® (aflibercept) as a treatment option for visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).  This drug has been shown in two licensing trials, COPERNICUS and GALILEO, to achieve the primary endpoint of gaining at least 15 letters on an eye chart in 55.3% and 60.2% of patients.”

“Patients with retinal vein occlusion and macular oedema can now be effectively treated with intravitreal Eyelea therapy.”


March 27th 2014

“The Pascal 577 nm Streamline laser Photocoagulator arrived at Moorfields Croydon today.  The Pascal laser device is equipped with the innovative Endpoint Management software for macular and オンライン カジノ retinal treatments, and this is a first for Moorfields Eye Hospital. We aim to provide a centre of excellence for retinal laser therapy for all patients being treated at “Moorfields at Croydon” as part of Moorfields South that links with the Croydon Diabetic Retinopathy Screening Service (DRSS).”

April 12th 2014

“The 1st Jetrea Users Group meeting  hosted by Alcon, Frankfurt, Germany.”

This forum provided an excellent insight into the real-world use of intravitreal Jetrea (Ocriplasmin) for both vitreomacular traction (VMT), and VMT with small macular holes in patients. Experts from Europe and the USA reported natural history data and clinical experiences of this new drug innovation. Key factors to improve the patient experience for Jetrea treatment include: patient selection; patient education and consent; and, patient expectation.


Friday May 2nd 2014

“Carl Zeiss Meditec has introduced the OPMI Lumera 700 and Rescan 700, surgical microscope that feature integrated intraoperative OCT (iOCT).”

Experienced first use 0f this intraoperative optical coherence tomography at Moorfields St Georges today. Real-time OCT imaging available for image-guided, minimally-traumatic retinal membrane dissection. A fantastic innovation that vitreoretinal surgeons can now develop and innovate for increasing surgical precision and maximising patient surgical outcomes.


Monday June 9th 2014

“Secondary Capsular IOL Course”

The Royal College of Ophthalmologists

October 17th 2014

“This all-day course will introduce ophthalmic surgeons to the latest developments in secondary lens implant surgery. The main surgery topic will include a comprehensive approach to scleral-haptic fixated IOL surgery.  Alternative techniques will include Artisan IOL surgery and conventional surgery.”

To book an appointment call +44 7717 203564 or email

Insurance Partners

Patient Feedback